Last reviewed · How we verify
Treprostinil Injectable Product
Treprostinil is a prostacyclin analogue that acts as a vasodilator and inhibits platelet aggregation.
Treprostinil is a prostacyclin analogue that acts as a vasodilator and inhibits platelet aggregation. Used for Treatment of pulmonary arterial hypertension, Treatment of chronic thromboembolic pulmonary hypertension.
At a glance
| Generic name | Treprostinil Injectable Product |
|---|---|
| Also known as | Remodulin |
| Sponsor | University of Arizona |
| Drug class | Prostacyclin analogue |
| Target | Prostacyclin receptor |
| Modality | Small molecule |
| Therapeutic area | Pulmonology |
| Phase | Phase 3 |
Mechanism of action
It works by binding to and activating the prostacyclin receptor, leading to relaxation of smooth muscle cells and vasodilation. This results in decreased blood pressure and reduced platelet aggregation.
Approved indications
- Treatment of pulmonary arterial hypertension
- Treatment of chronic thromboembolic pulmonary hypertension
Common side effects
- Headache
- Nausea
- Dizziness
- Flushing
- Pain in extremity
Key clinical trials
- DelIVery for Pulmonary Arterial Hypertension (PAH) & Continued Support Study (NA)
- Trial to Evaluate Parenteral Treprostinil and Riociguat on Right Ventriculo-vascular Coupling and Morphology in Those With Advanced PAH (PHASE3)
- Study of Remodulin® in Pediatric Pulmonary Hypertension With Single Ventricular Physiology After Fontan Surgery (PHASE3)
- Transition From Injectable Prostacyclin Medication to Inhaled Prostacyclin Medication (PHASE4)
- Safety of Transition From Selexipag to Remodulin® Then Oral Treprostinil in Symptomatic Adult PAH (PHASE2)
- Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies
- Study of Remodulin in Patients With Critical Limb Ischemia With No Planned Revascularization Procedures (PHASE3)
- Effects of Remodulin in Patients With Critical Limb Ischemia Following a Vein Bypass Graft (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Treprostinil Injectable Product CI brief — competitive landscape report
- Treprostinil Injectable Product updates RSS · CI watch RSS
- University of Arizona portfolio CI